8-K current report · filed Aug 3, 2026

Twist Bioscience Corp (TWST) 8-K Current Report: August 3, 2026

Item EX-99.1Item 2.02TWST overview

Short answer

Twist Bioscience Corp (TWST) filed an 8-K current report with the SEC on August 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended June 30, 2026.

Twist Bioscience Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended June 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1
  • Earnings release provides investors the basis for assessing quarterly operating performance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 FY26 revenue $118.4M, up 23% YoY; 14th consecutive quarter of sequential growth
  • DSPS revenue $56.6M, up 39%; NGS revenue $61.8M, up 12%, indicating stronger synthesis momentum
  • Gross margin 52.8%, up 120 basis points sequentially, while adjusted EBITDA loss widened to $11.3M
  • FY26 revenue guidance raised to $456–$457M; Q4 guidance implies $123–$124M revenue and adjusted EBITDA breakeven
  • Cash, cash equivalents and short-term investments approximately $167M at June 30, 2026; net loss $35.1M included no prior-year spinout gain

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Twist Bioscience Corp 8-K filings

Get the next TWST 8-K as it lands

Follow TWST for push alerts, or ask the research agent what this filing means.